Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene.
- Author:
Ya-zhen QIN
1
;
Yan-rong LIU
;
Jin-lan LI
;
Hui WANG
;
Yan CHANG
;
Jia-yu FU
;
Guo-rui RUAN
;
Hui-lin SHI
;
Jing-ying QIU
;
Dao-pei LU
;
Shan-shan CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Fusion Proteins, bcr-abl; genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; genetics; Male; Molecular Sequence Data; Philadelphia Chromosome; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA
- From: Chinese Journal of Hematology 2004;25(7):409-412
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).
METHODSBy using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR). The RT-PCR products sequencing was performed, the DNA sequences were analyzed in Genebank and the bcr and abl sequences at the fusion site were identified. DNA was amplified by PCR using a set of primers designed according to the sequencing result of RT-PCR products.
RESULTSTwo patients showed typical manifestations of CML-CP. Their RT-PCR products were different from usual M- or micro -type; one was longer than M-bcr/abl but shorter than micro -bcr/abl, the other one was shorter than M-bcr/abl. The RT-PCR products sequencing showed that both products contained bcr and abl gene sequences. The first patient's bcr gene was broken within exon 18, and fused to abl gene exon 2(a2), and a 40 bp of partial abl intron 1b fragment was inserted between them, resulting in a novel in-frame bcr/abl fusion transcript-e18-int-a2 which has not been reported in the literature so far. In the second patient, deletion of abl exon2(a2) led to exon 13(b2) of bcr gene fusing with abl exon 3(a3).
CONCLUSIONUncommon bcr/abl fusion gene may occur in typical Ph(+) CML patient.